Zoledronic acid for adjuvant use in patients with breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 333-349

  Ressler, Sigrun ^a   Mlineritsch, Brigitte ^a   Greil, Richard ^a  

^a Private Medical University Salzburg   (Austria)

Author keywords

adjuvant therapy; anti tumor activity; bone loss; breast cancer; zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BONVIA; CLODRONIC ACID; CYTOTOXIC AGENT; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETIDRONIC ACID; GERANYLTRANSFERASE; GLUCOCORTICOID; GOSERELIN; HORMONE INHIBITOR; IBANDRONIC ACID; INTERLEUKIN 2; LETROZOLE; MEVALONIC ACID; MINODRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RAS PROTEIN; RISEDRONIC ACID; TAMOXIFEN; TILUDRONIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ADVANCED CANCER; ANAPHYLACTIC SHOCK; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLURRED VISION; BONE CANCER; BONE DENSITY; BONE MARROW TUMOR; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BRADYCARDIA; BREAST CANCER; BREAST TUMOR; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; CREATININE BLOOD LEVEL; CYTOSTASIS; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ELECTROLYTE DISTURBANCE; EPISCLERITIS; EYE TOXICITY; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATURIA; HETEROTOPIC OSSIFICATION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPESTHESIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOMODULATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSOMNIA; IRITIS; JAW OSTEONECROSIS; KIDNEY CANCER; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEG EDEMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICROMETASTASIS; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE CRAMP; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PANCYTOPENIA; PARESTHESIA; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROTEINURIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REPEATED DRUG DOSE; RESTLESSNESS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN REDNESS; SOLID TUMOR; SOMNOLENCE; SORE THROAT; SPINAL CORD COMPRESSION; STOMATITIS; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; UREA BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; UVEITIS; VERTIGO; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES;

EID: 79952914994     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.13     Document Type: Article

References (143)

1. Jemal A, Siegel R, Xu J, et al. Cancer Statistics 2010. CA Cancer J. Clin. 60(5), 277-300 (2010)
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 9, R28 (2007)
3. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356, 1670-1674 (2007) (Pubitemid 46631679)
4. Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 113(2), 238-246 (2008)
5. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat. Rev. Clin. Oncol. 7(1), 22-36 (2009)
6. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol. 26(12), 1987-1992 (2008)
7. Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr. Relat. Cancer 16(4), 1091-1102 (2009)
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005) (Pubitemid 41464705)
9. Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7, 153 (2007)
10. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28, 509-918 (2010)
11. Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J. Clin. Oncol. 28, 346-347 (2010)
12. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 2, 1102-1109 (1984) (Pubitemid 14022697)
13. Early Breast Cancer Trialists? Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005)
14. Early Breast Cancer Trialists? Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview over randomized trials among 28896 women. N. Engl. J. Med. 319, 1681-1692 (1988)
15. Lester J, Dodwell D, McCloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat. Rev. 3, 115-142 (2005) (Pubitemid 40542890)
16. Greil R. The dark side of the moon -the side effects of therapy in a dynamic era of breast cancer management. Breast Care 4, 144-147 (2009)
17. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit. Rev. Oncol. Hemat. 69, 73-82 (2008)
18. Siris ES, Chen YT, Abbott TA. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch. Intern. Med. 164, 1108-1112 (2004) (Pubitemid 38668990)
19. Bock O, Felsenberg D. Biphosphonates in management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin. Interv. Aging 3, 279-297 (2008) (Pubitemid 352037868)
20. Pavlakis N, Schmidt R, Stockler M. Biphosphonates for breast cancer. Cochrane Database Syst. Rev. 3, CD003474 (2005)
21. Rosen LS, Gordon GH, Dugan W. Zoledronic acid is superior to pamidronate for the treatment of bone metastasis in breast carcinoma with at least one osteolytic lesion. Cancer 100, 36 (2004)
22. Brufsky A, Bundred N, Coleman R. Integrated analysis of zoledronic acid for prevention of aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13, 503-514 (2008) (Pubitemid 351872868)
23. Frassoldati A, Brufsky A, Bundred N. The effect of zoledronic acid on aromatase inhibitor -associated bone loss in postmenopausal women. ESMO (2008) (Abstract 185PD)
24. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol. 9, 840-849 (2008)
25. Hershman DL, McMahon DJ, Crew KD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol. 26, 4739-4745 (2008)
26. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy. ASCO (2008) (Abstract 512)
27. Brufsky A, Harker WG, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women. SABCS (2009) (Abstract 4083)
28. Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor associated bone loss in postmenopausal women. Presented at: ASCO 2009 Breast Cancer Symposium. San Francisco, CA, USA, 8-10 October 2009 (Abstract 213)
29. Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women. Breast Cancer 117, 603-609 (2009)
30. Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 update on the role of biphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 4042-4057 (2003) (Pubitemid 46606220)
31. Ellis GK, Bone HG, Chlebowski R. Randomised trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008)
32. Stopeck A, de Boer R, Fujiwara Y. A comparison of denusomab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Cancer Res. 69(Suppl. 4), 490 (2009) (Abstract 422)
33. Drake MT, Bart LC, Khosla S, et al. Bisphosphonates: mechanisms of action and role in clinical practice. Mayo Clin. Proc. 83, 1032-1045 (2008)
34. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13(2), 187-195 (2008) (Pubitemid 351342583)
35. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296, 235-242 (2004) (Pubitemid 32112446)
36. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanisms of nitrogen containing bisphosphonates as antiosteoporosis drugs. Proc. Natl Acad. Sci. USA 103, 7829-7834 (2006)
37. Holstein SA, Wohlford-Lenane CL, Wiemer DF. Isoprenoid pyrophosphate analogues regulate expression of ras-related proteins. Biochemistry 42(15), 4384-4391 (2003) (Pubitemid 36457605)
38. Winter-Vann AM, Casey PJ. Postprenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5, 405-412 (2005) (Pubitemid 40637832)
39. Hall A. Rho GTPases and the actin cytoskeleton. Science 279(5350), 509-514 (1998) (Pubitemid 28067271)
40. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13(4), 581-589 (1998) (Pubitemid 28163009)
41. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 4, 30-34 (2002) (Pubitemid 34097554)
42. Roelofs, AJ, Thompson K, Gordon S, et al. Molecular mechanisms of actions of bisphosphonates: current status. Clin. Cancer Res. 12, 6222-6230 (2006)
43. Mönkkönen H, Lehenkari PP, Kellinsalmi M, et al. A new mechanism of action for bisphosphonates: ApppI dedicated cytotoxicity of N-BPs. Bone 34, S66-S67 (2006)
44. Mönkkönen H, Ottewell PD, Kuokkanen J, et al. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci. 81(13), 1066-1070 (2007) (Pubitemid 47418845)
45. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12, 220-229 (1998) (Pubitemid 28108075)
46. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82, 1459-1468 (2000) (Pubitemid 30175914)
47. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 88, 1971-1978 (2003) (Pubitemid 36829676)
48. Tanaka T, Kawashima H, Onishi K, et al. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells. Anticancer Res. 29, 1089-1094 (2009)
49. Green R. Biphosphonates: preclinical Review. Oncologist 9(4), 3-13 (2004)
50. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 104, 623-633 (2004) (Pubitemid 39578752)
51. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden, and angiogenesis, and increased survival. J. Bone Miner. Res. 18, 482-492 (2003) (Pubitemid 36241065)
52. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9, 2893-2897 (2003) (Pubitemid 36993246)
53. Santini D, Vincenzi B, Hannon RA, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol. Rep. 15, 1351-1357 (2006)
54. Hirbe AC, Roelofs AJ, Floyd DH, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 44, 908-916 (2009)
55. Hirbe AC, Roelofs AJ, Caraglia M, et al. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin. Pharmacother. 11, 141-154 (2010)
56. Senaratne SG, Masni JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer 86, 1479-1486 (2002) (Pubitemid 34548073)
57. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15, 2211-2221 (2000)
58. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373, 231-241 (2000) (Pubitemid 30046509)
59. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonateinduced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28, 465-473 (2001) (Pubitemid 32409997)
60. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst. 99, 322-330 (2007) (Pubitemid 47073494)
61. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84, 1126-1134 (2001) (Pubitemid 32448513)
62. Vogt U, Wassmann K, Bosse U, et al. Enhancement of breast tumor growth inhibition (BTGI) in vitro through combination of CMF, epirubicin/ cyclophosphamide (EC), epirubicin/paclitaxel (ET) and epirubicin/docetaxel (EDoc) with ibandronate (IB) or zoledronic acid (ZOL). Proc. Am. Soc. Clin. Oncol. 22, (2003)
63. Jagdev SP, Croucher P, Coleman RE, et al. Zoledronate induces apoptosis of breast cancer cells in vitro-evidence for additive and synergistic effects with taxol and tamoxifen. Proc. Am. Soc. Clin. Oncol. 19, 664a (2000)
64. Winter MC, Holen I, Coleman RE, et al. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev. 34, 453-475 (2008)
65. Neville-Webbe HL, Coleman RE, Holen I, et al. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br. J. Cancer 102, 1010-1017 (2010)
66. Ottewell PD, Deux B, Mönkkönen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res. 14, 4658 (2008)
67. Wakchoure S, Merell MA, Aldrich W, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res. 12, 862-868 (2006)
68. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47, 31-39 (2005) (Pubitemid 39643239)
69. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59(2), 180-191 (2008) (Pubitemid 351181343)
70. Nobuyuki H, Hiraga T, Williams PJ, et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J. Bone Miner. Res. 16(Suppl. 1), S191 (2001)
71. Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif. Tissue Int. 73, 315-318 (2003) (Pubitemid 37409416)
72. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat. Rev. 34, 19-21 (2008)
73. Coleman R. On the horizon: can bisphosphonates prevent bone metastases? Breast 16, 21-27 (2007) (Pubitemid 350194029)
74. Bundred N, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer 112, 1001-1010 (2008) (Pubitemid 351304583)
75. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(22), 2367 (2009)
76. Coleman R, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 102, 1099-1105 (2010)
77. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41, 326-331 (1987)
78. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384-392 (2000) (Pubitemid 30463353)
79. Kunzmann V, Bauer E, Wilhelm M. gd T cell stimulation by pamidronate. N. Engl. J. Med. 340, 737-738 (1999)
80. Born WK, Reardon CL, O?Brien RL. The function of gd T cells in innate immunity. Curr. Opin. Immunol. 18, 31-38 (2006)
81. Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gd cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163-168 (2003) (Pubitemid 36152311)
82. Casetti R, Martino A. The plasticity of gd T cells: innate immunity, antigen presentation and new immunotherapy. Cell. Mol. Immunol. 5(3), 161-170 (2008)
83. Galluzzo S, Santini D, Vincenzi B, et al. Immunmodulating role of bisphosphonates on human g d T cells: an intringuing and promising aspect of their antitumor activity. Expert Opin. Ther. Targets 11, 941-954 (2007) (Pubitemid 47054489)
84. Caccamo N, Meraviglia S, Scarpa F, et al. Aminobisphosphonate-activated gd T cells in immunotherapy of cancer: doubts no more. Expert Opin. Biol. Ther. 8(7), 875-883 (2008) (Pubitemid 352007000)
85. Sato K, Kimura S, Yokota A, et al. Cytotoxic effects of gd T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116(1), 94-99 (2005) (Pubitemid 40827760)
86. Hayday AC. gd cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18, 975-1026 (2000) (Pubitemid 30365402)
87. Wilhelm M, Kunzmann V, Eckstein S, et al. gd T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200-206 (2003) (Pubitemid 36759655)
88. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67 (15), 7450-7457 (2007) (Pubitemid 47206575)
89. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vg9Vd2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exper. Immunol. 161(2), 290-297 (2010)
90. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol. 11, 421-429 (2010)
91. Hirbe A, Morgan FA, Uluckan O, et al. Skeletal complications of breast cancer therapies. Clin. Cancer Res. 12, 6309-6314 (2006)
92. Käkönen SM, Mundy G. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97, 834-839 (2003) (Pubitemid 36125820)
93. Braun S, Pantel K, Müller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N. Engl. J. Med. 342, 525-533 (2000) (Pubitemid 30117892)
94. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 21, 3469-3478 (2003) (Pubitemid 46594079)
95. Rack B, Schindlbeck C, Strobl B, et al. Efficacy of zoledronate in treating persisting isolated tumour cells in bone marrow in patients with breast cancer. Dtsc. Med. Wochenschr. 133, 285-289 (2008) (Pubitemid 351315392)
96. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Cancer Res. 68, (2007) (Abstract 510)
97. Greenberg S, Park JW, Melisko ME, et al. Effect of adjuvant zoledronic acid on disseminated tumor cells in the bone marrow of women with early stage breast cancer: updated results. ASCO (2010) (Abstract 1002)
98. Green, JR. Moiler, K. Jaeggi, KA. Preclinical pharmacology of CGP 42? 446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9, 745-751 (1994)
99. Green R. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. Organometallic Chem. 690, 2439-2448 (2005)
100. Russel RG. Bisphosphonates: from bench to bedside. Ann. NY Acad. Sci. 1068, 367-401 (2006)
101. Glatt M. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. Eur. Cells Materials 296, 238-242 (2000)
102. Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. Bone Miner. Res. 14, 1557-1561 (1999) (Pubitemid 29416682)
103. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19, 558-567 (2001) (Pubitemid 32112871)
104. Saad F, Donald M, Gleason R, et al. A randomized placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002)
105. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J. Natl Cancer Inst. 96, 879-882 (2004) (Pubitemid 38807610)
106. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial -the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150-3157 (2003) (Pubitemid 46606297)
107. Rosen L, Gordon D, Tchekmediyan S, et al. Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone 34(1), S89 (2004) (Abstract 73)
108. Lipton A, Zheng M, Seaman J, et al. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98, 962-969 (2004)
109. Lipton A, Seaman J, Zheng M, et al. Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Bone 24(1), S62 (2004) (Abstract 28)
110. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98, 1735-1744 (2003) (Pubitemid 37238631)
111. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 23, 3314-3321 (2005)
112. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and bone metastases. Clin. Cancer Res. 9, 2394 (2003)
113. Chen T, Berenson J, Vescio R, et al. Pharmacokinetiks and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Clin. Pharmacol. 42, 1228-1236 (2002) (Pubitemid 35205058)
114. Skerjanec A, Berenson J, Major P, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. Clin. Pharmacol. 43, 154-162 (2003) (Pubitemid 36125942)
115. Berenson J, Hirschberg R. Safety and Convenience of a 15 minute infusion of zoledronic acid. Oncologist 9(3), 319-329 (2004) (Pubitemid 38756880)
116. ®, Summary of product characteristics. Novartis Pharma AG, Switzerland (2010)
117. Chang JT, Green L, Beitz J, et al. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 17, 1676-1679 (2003)
118. Smetana S, Michlin A, Rosenman E, et al. Pamidronate induced nephrotoxic tubular necrosis -a case report. Clin. Nephrol. 61(1), 63-67 (2003)
119. Wakchoure S, Merell MA, Aldrich W, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res. 12, 862-868 (2006)
120. Zaghloul MS, Boutrus R, El-Hosieny H. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients. J. Clin. Oncol. 26 (2008) (Abstract 5033)
121. Aviles A, Nambo MJ, Neri N. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med. Oncol. 24, 227-230 (2007) (Pubitemid 350135975)
122. Eidtmann H, Bundred NJ, de Boer R, et al. Efficacy of zolerdronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol. 10, 1093 (2010)
123. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The Azure Trial (BIG 01/04). Cancer Res. 70(Suppl. 4), S4-S5 (2010)
124. Mauri D, Valachis A, Polyzos NP, et al. Does adjuvant bisphosphonate in adjuvant breast cancer modify the natural course of the disease ? A metaanalysis of randomized controlled trials. J. Natl Compr. Cancer Net. 8, 279-286 (2010)
125. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91, 1191-1200 (2001)
126. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356(18), 1809-1822 (2007) (Pubitemid 46698462)
127. Cummings SR, Schwartz AV, Black DM, et al. Alendronate and atrial fibrillation (letter). N. Engl. J. Med. 356(18), 1895-1896 (2007)
128. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168(8), 826-831 (2008) (Pubitemid 351649266)
129. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336(7648), 813-816 (2008) (Pubitemid 351548223)
130. Woo SB, Hellstein JW, Kalmar JR, et al. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws published correction appears in Ann. Intern. Med. 145(3), 235 (2006)
131. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7), 968-971 (2006) (Pubitemid 44023154)
132. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21(7), 1545-1548 (2007) (Pubitemid 46965296)
133. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22(10), 1479-1491 (2007) (Pubitemid 351229318)
134. Gralow JR, Biermann S, Farooki A, et al. NCCN Task Force Report: bone health in cancer care. J. Nat. Compr. Cancer Network 7(3), S1-31 (2009)
135. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63(11), 1567-1575 (2005) (Pubitemid 41525412)
136. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23(34), 8580-8587 (2005) (Pubitemid 46211499)
137. Lenart BA, Lorich DG, Lane JM, et al. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 358, 1304-1306 (2008) (Pubitemid 351439247)
138. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. 91(11), 2556-2561 (2009)
139. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362, 1761-1771 (2010)
140. Lipton A. Should biphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res. Treat. 10, 935-937 (2010)
141. Fox R. Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea? Curr. Oncol. Rep. 12, 1-3 (2010)
142. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer 90, 1133-1137 (2004) (Pubitemid 38496803)
143. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14, 1399-1405 (2003) (Pubitemid 37185286)